目的 評價中國科學院合肥腫瘤醫(yī)院新型抗腫瘤藥的臨床使用情況和用藥趨勢，為促進臨床合理用藥提供依據(jù)。方法 采用回顧性的方法分析2018-2022年中國科學院合肥腫瘤醫(yī)院臨床使用的新型抗腫瘤藥的消耗量、銷售金額、用藥頻度（DDDs）、限定日費用（DDC）及藥品銷售金額排序（B）/DDDs排序（A）情況。結(jié)果 2018-2022年，醫(yī)院新型抗腫瘤藥物的品種數(shù)和銷售金額呈逐年增長趨勢，品種數(shù)從2018年的11種增加到2022年的49種，銷售金額從2018年的270.34萬元增長至2022年的2 543.00萬元。2018-2019年，甲磺酸阿帕替尼片的銷售金額及其DDDs排序均居第1位；2020-2021年，注射用卡瑞利珠單抗的銷售金額排序居第1位，其DDDs 2021年居第1位。2022年，貝伐珠單抗注射液的銷售金額排序居第1位，其DDDs排序居第3位。吉非替尼片銷售金額不斷下降，但其DDDs在2018-2021年均居前3位。2018-2022年，中國科學院合肥腫瘤醫(yī)院大部分新型抗腫瘤藥各品種的DDC處于逐年降低趨勢。2020年卡瑞利珠單抗B/A<1，患者經(jīng)濟負擔較重，2021年入圍國家醫(yī)保談判品種后，價格大幅度下降，B/A達到1，2022年B/A>1；重組人血管內(nèi)皮抑制素、貝伐珠單抗的B/A均<1，可能與其近年來銷售金額增加有關(guān)；厄洛替尼、?？颂婺岬腂/A均>1，說明其價格更低、使用頻率更高，大部分藥品的DDC相對穩(wěn)定，B/A接近于1，提示其銷售金額與DDDs的同步性總體較好。結(jié)論 中國科學院合肥腫瘤醫(yī)院新型抗腫瘤藥的臨床使用相對合理，需要加強抗腫瘤藥物臨床應用管理，建立相關(guān)考核指標體系并納入績效考核，從而確保臨床使用新型抗腫瘤藥物安全、有效、經(jīng)濟。

Objective To evaluate the clinical use and drug use trend of new anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences, so as to provide a basis for promoting clinical rational drug use. Methods Using a retrospective method, the consumption, sales amount, DDDs, DDC, and B/A of new anti-tumor drugs used in Hefei Cancer Hospital, Chinese Academy of Sciences were statistically analyzed from 2018 to 2022. Results From 2018 to 2022, the variety and sales amount of new anti-tumor drugs in hospital increased year by year. The number of varieties increased from 11 in 2018 to 49 in 2021, and the sales amount increased from 2.703 4 million yuan in 2018 to 25.43 million yuan in 2022. From 2018 to 2019, the sales value and its DDDs of Apatinib Mesylate Tablets ranked first. From 2020 to 2021, the sales amount of Camrelizumab for injection ranked first, and its DDDs ranked first in 2021. In 2022, the sales amount of Bevacizumab Injection ranked first, and its DDDs ranked third. The sales amount of Gefitinib Tablets continues to decline, but its DDDs ranks among the top 3 from 2018 to 2021. From 2018 to 2022, the DDC of most of the new anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences was decreasing year by year. In 2020, the B/A of camrelizumab is far less than 1, indicating that patient's economic burden is heavy. After entering the national medical insurance negotiation category in 2021, the price dropped significantly, and B/A reached 1, and B/A > 1 in 2022. B/A of recombinant human endostatin and bevacizumab were all lower than 1, which may be related to the increase in sales amount in recent years. The B/A of erlotinib and icotinib were all > 1, indicating that their prices were lower and their use frequency was higher. The DDC of most drugs was relatively stable, and B/A was close to 1, indicating that the synchronization between their sales sum and DDDs was generally good. Conclusion The clinical use of new anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences is relatively reasonable, and it is necessary to strengthen the clinical application management of anti tumor drugs, establish the relevant assessment index system and incorporate it into the performance assessment, so as to ensure the safety, effectiveness and economy of clinical use of new anti-tumor drugs.

R979.1